caa a22 4500 477069916 CHVBK 20180405111422.0 cr unu---uuuuu 170330e19960901xx s 000 0 eng 10.1007/BF01691957 doi (NATIONALLICENCE)springer-10.1007/BF01691957 Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group a streptococcal tonsillopharyngitis in children [Elektronische Daten] [D. Adam, H. Scholz, C. Aspe, H. Berzel, D. Bulle, H. Fritz, V. Grosse, W. Hartmann, R. Heil, P. Hirschbrunn, U. Hübschmann-Mehl, J. Just, A. Kielhorn, B. Knauer, L. Maurer, K. Müller, G. Niehaus, D. Onken, W. Raff, J. Reineke, A. Schulze-Buxloh, D. Schumann, M. Steiner, C. Szdzuy, P. van Stiphout, M. Weh, H. Winter, P. Wolff, M. Zinke] In a randomized, prospective, multicenter trial, 227 children ranging in age from 3 to 17 years who had tonsillopharyngitis and a throat culture positive for group A beta-hemolytic streptococci (GABHS) were treated with erythromycin estolate (40 mg/kg/d in two divided doses for five days) or penicillin V (30 mg/kg/d in three divided doses for ten days). Clinical signs and symptoms of tonsillopharyngitis were recorded, and throat cultures were obtained before treatment as well as one to three days and six weeks after treatment. Clinical success (cure and improvement) was observed on days 6 to 8 in 100 of 102 (98%) assessable children treated with erythromycin estolate and on days 11 to 13 in 97 of 99 (98%) assessable children treated with penicillin V. Of all patients showing clinical success, 11 were rated as improved, all of whom were treated with erythromycin estolate. There was a trend towards increased use of analgesic treatment in the erythromycin estolate group (41 % vs 33%). On completion of treatment, the rate of eradication of GABHS was 83.3% in the erythromycin estolate group compared with 87.9% in the penicillin V group. The difference is not significant but does not take into account patients excluded because of erythromycin resistance (3.7%). Clinical recurrence was observed in 11 (10.8%) patients treated with erythromycin estolate and in 6 (6.1%) patients treated with penicillin V (non-significant difference). Compliance in the erythromycin estolate group was statistically superior to that in the penicillin V group. The incidence and nature of adverse events were similar in both treatment groups. MMV Medizin Verlag GmbH, 1996 Adam D. Dr. von Haunersches Kinderspital der Universität München, Lindwurmstraße 4, 80337, Munich, Germany aut Scholz H. Institut für Infektiologie, Mikrobiologic und Hygiene, Klinikum Berlin-Buch, Wiltbergstraße 50, 13122, Berlin-Buch, Germany aut Aspe C. aut Berzel H. aut Bulle D. aut Fritz H. aut Grosse V. aut Hartmann W. aut Heil R. aut Hirschbrunn P. aut Hübschmann-Mehl U. aut Just J. aut Kielhorn A. aut Knauer B. aut Maurer L. aut Müller K. aut Niehaus G. aut Onken D. aut Raff W. aut Reineke J. aut Schulze-Buxloh A. aut Schumann D. aut Steiner M. aut Szdzuy C. aut van Stiphout P. aut Weh M. aut Winter H. aut Wolff P. aut Zinke M. aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/9(1996-09-01), 712-717 0934-9723 15:9<712 1996 15 10096 https://doi.org/10.1007/BF01691957 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01691957 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Adam D. Dr. von Haunersches Kinderspital der Universität München, Lindwurmstraße 4, 80337, Munich, Germany aut NATIONALLICENCE 700 1- Scholz H. Institut für Infektiologie, Mikrobiologic und Hygiene, Klinikum Berlin-Buch, Wiltbergstraße 50, 13122, Berlin-Buch, Germany aut NATIONALLICENCE 700 1- Aspe C. aut NATIONALLICENCE 700 1- Berzel H. aut NATIONALLICENCE 700 1- Bulle D. aut NATIONALLICENCE 700 1- Fritz H. aut NATIONALLICENCE 700 1- Grosse V. aut NATIONALLICENCE 700 1- Hartmann W. aut NATIONALLICENCE 700 1- Heil R. aut NATIONALLICENCE 700 1- Hirschbrunn P. aut NATIONALLICENCE 700 1- Hübschmann-Mehl U. aut NATIONALLICENCE 700 1- Just J. aut NATIONALLICENCE 700 1- Kielhorn A. aut NATIONALLICENCE 700 1- Knauer B. aut NATIONALLICENCE 700 1- Maurer L. aut NATIONALLICENCE 700 1- Müller K. aut NATIONALLICENCE 700 1- Niehaus G. aut NATIONALLICENCE 700 1- Onken D. aut NATIONALLICENCE 700 1- Raff W. aut NATIONALLICENCE 700 1- Reineke J. aut NATIONALLICENCE 700 1- Schulze-Buxloh A. aut NATIONALLICENCE 700 1- Schumann D. aut NATIONALLICENCE 700 1- Steiner M. aut NATIONALLICENCE 700 1- Szdzuy C. aut NATIONALLICENCE 700 1- van Stiphout P. aut NATIONALLICENCE 700 1- Weh M. aut NATIONALLICENCE 700 1- Winter H. aut NATIONALLICENCE 700 1- Wolff P. aut NATIONALLICENCE 700 1- Zinke M. aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/9(1996-09-01), 712-717 0934-9723 15:9<712 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer